Christopher U Jones, M.D., FACR
Dr. Christopher Jones is a board-certified radiation oncologist who specializes in the use of ionizing radiation to treat cancer, focusing on tumors of the head and neck, prostate, and brain. He investigates optimal use of radiation therapy (radiotherapy) techniques including intensity modulated radiation therapy (IMRT), high-dose brachytherapy, and image-guided radiation therapy. Dr. Jones is a Principal Investigator for Radiation Therapy Oncology Group (RTOG) National Cancer Institute-sponsored oncology group clinical trials. He has authored numerous publications and abstracts on radiotherapy and imaging techniques to assess cancer progression, predict tumor recurrence after surgery and radiotherapy, and visualize response to treatment. Dr. Jones lectures nationally and internationally on the role of radiation therapy in the management of head and neck cancers.
Clinical trials
- Clinical trial
Adjuvant Astrocytomas Grade 3 A072301
Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination With the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas
Status: Open to Enrollment
- Clinical trial
Adjuvant Endometrial Cancer NRG GY032
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
Status: Open to Enrollment
- Clinical trial
Locally Advanced Non-Small Cell Lung Cancer NRG-LU008
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Status: Open to Enrollment
- Clinical trial
Locally Advanced Pancreas Cancer GI011
A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
Status: Open to Enrollment
- Clinical trial
Locally Advanced RTOG 1216
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Status: Closed to Enrollment